TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, S.A. (20240245800). HIGHLY SPECIFIC RABBIT SINGLE -DOMAIN ANTIBODIES FOR DRUG DELIVERY IN IMMUNOTHERAPY APPLICATIONS simplified abstract

HIGHLY SPECIFIC RABBIT SINGLE -DOMAIN ANTIBODIES FOR DRUG DELIVERY IN IMMUNOTHERAPY APPLICATIONS

Organization Name

TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, S.A.

Inventor(s)

Frederico Nuno Castanheira Aires Da Silva of Lisboa (PT)

Joana Nunes Ribeiro Dias Gomes of Lisboa (PT)

[[:Category:Ana Filipa Santos Andr� of Alvor (PT)|Ana Filipa Santos Andr� of Alvor (PT)]][[Category:Ana Filipa Santos Andr� of Alvor (PT)]]

Sandra Isabel Rodrigues De Aguiar of Lisboa (PT)

Soraia Rafaela Santiago De Oliveira of Fernão Ferro (PT)

Luís Manuel Morgado Tavares of Linda-a-Velha (PT)

HIGHLY SPECIFIC RABBIT SINGLE -DOMAIN ANTIBODIES FOR DRUG DELIVERY IN IMMUNOTHERAPY APPLICATIONS - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240245800 titled 'HIGHLY SPECIFIC RABBIT SINGLE -DOMAIN ANTIBODIES FOR DRUG DELIVERY IN IMMUNOTHERAPY APPLICATIONS

The present disclosure involves the development of drug delivery systems using single domain antibodies (sdAbs) for targeted therapy in cancer and central nervous system (CNS) pathologies.

• Antibody-drug conjugates (ADCs) with high selectivity and efficiency are created for cancer therapy using sdAbs derived from rabbits.
• The ADC molecules for cancer therapy contain a potent cytotoxic payload, SN38, conjugated with exposed cysteine residues on the sdAbs.
• Drug delivery systems targeting BBB endothelial cell receptors in the CNS are developed using sdAbs conjugated to liposomes encapsulating drugs for efficient BBB translocation.

Potential Applications: - Targeted cancer therapy with high selectivity and efficiency. - Treatment of CNS pathologies by delivering drugs across the blood-brain barrier.

Problems Solved: - Enhancing the specificity and efficacy of drug delivery systems. - Overcoming the challenges of crossing the blood-brain barrier for CNS treatments.

Benefits: - Improved therapeutic outcomes with targeted drug delivery. - Minimized off-target effects and enhanced drug efficacy.

Commercial Applications: Title: Innovative Drug Delivery Systems Using Single Domain Antibodies This technology can be applied in pharmaceutical companies for developing targeted cancer therapies and CNS treatments, potentially leading to new drug formulations and treatment strategies.

Questions about the technology: 1. How do single domain antibodies enhance the specificity of drug delivery systems? 2. What are the advantages of using rabbit-derived sdAbs in developing ADCs for cancer therapy?

Original Abstract Submitted

the present disclosure relates to the development of drug delivery systems comprising single domain antibodies (sdabs). for this purpose, antibody-drug conjugates (adcs) are provided with high selectivity and efficiency to be used advantageously in cancer therapy, and a drug-delivery system targeting the central nervous system (cns) pathologies. the adc molecules developed for therapy, namely for cancer therapy are obtained from rabbit derived sdabs comprising a potent cytotoxic payload, a sn38 small molecule conjugated with the free exposed cysteine at position 80, 23 or 88 of the vframework. the drug delivery systems developed targeting the bbb endothelial cell receptors of the central nervous system (cns) comprise rabbit derived single-domain antibodies (sdab) conjugated at the surface of liposomes encapsulated with a suitable drug enabling an efficient blood-brain barrier (bbb) translocation. the respective process of production is also herein disclosed. therefore, the present disclosure is in the domain of genetic engineering, biotechnology, pharmaceuticals and medicine.